FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Roti patents



      
           
This page is updated frequently with new Roti-related patent applications. Subscribe to the Roti RSS feed to automatically get the update: related Roti RSS feeds. RSS updates for this page: Roti RSS RSS


Date/App# patent app List of recent Roti-related patents
05/21/15
20150141760
 Systems and methods for treating a carotid artery patent thumbnailnew patent Systems and methods for treating a carotid artery
Systems and methods are adapted for treating the carotid artery. The systems include interventional catheters and blood vessel access devices that are adapted for transcervical insertion into the carotid artery.
Silk Road Medical, Inc.
05/21/15
20150141501
 Ultrapure tetrahydrocannabinol-11-oic acids patent thumbnailnew patent Ultrapure tetrahydrocannabinol-11-oic acids
This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceutics Inc.
05/21/15
20150140161
 Methods of improving tolerance related to feeding in an infant, toddler, or child patent thumbnailnew patent Methods of improving tolerance related to feeding in an infant, toddler, or child
Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component..
Abbott Laboratories
05/21/15
20150137032
 Process for producing heat-treated vinylidene fluoride polymer powder and process for producing vinylidene fluoride polymer solution patent thumbnailnew patent Process for producing heat-treated vinylidene fluoride polymer powder and process for producing vinylidene fluoride polymer solution
The present invention relates to a process for producing a vinylidene fluoride polymer solution, which involves dissolving heat-treated vinylidene fluoride polymer powder into an aprotic polar solvent. The heat-treated vinylidene fluoride polymer powder is obtained by heat treating raw vinylidene fluoride polymer powder at such a temperature that the temperature of the vinylidene fluoride polymer powder is not less than 125° c.
Kureha Corporation
05/14/15
20150132466
 Nutritional products including a novel fat system including fatty acids patent thumbnailNutritional products including a novel fat system including fatty acids
Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component..
05/14/15
20150131889
 Necrotic cell region detection apparatus and  the same, and non-transitory computer readable storage medium to store a necrotic cell region detection program patent thumbnailNecrotic cell region detection apparatus and the same, and non-transitory computer readable storage medium to store a necrotic cell region detection program
A necrotic cell region detection apparatus includes an image acquiring unit, a segmentation unit, a band separate unit, a feature value calculating unit, a luminance calculating unit, and a judging unit. The image acquiring unit acquires a cell image.
05/07/15
20150127068
 Nerve stimulator system patent thumbnailNerve stimulator system
Devices, systems and methods for applying electrical impulse(s) to one or more selected nerves are described. An electrical stimulator is introduced through a to a target location within, adjacent to, or in close proximity with, the carotid sheath.
Electrocore, Llc
05/07/15
20150126622
 Blood biomarkers for necrotizing enterocolitis patent thumbnailBlood biomarkers for necrotizing enterocolitis
Necrotizing enterocolitis (nec) biomarkers, nec biomarker panels, and methods for obtaining a nec signature for a sample are provided. Also provided are methods, compositions, and kits for making a necrotizing enterocolitis (nec) assessment of an individual, e.g.
The Board Of Trustees Of The Leland Stanford Junior University
04/30/15
20150119576
 Method for production of 3-hydroxypropan-1-one compound,  production of 2-propen-1-one compound and  production of isoxazoline compound patent thumbnailMethod for production of 3-hydroxypropan-1-one compound, production of 2-propen-1-one compound and production of isoxazoline compound
There is provided a novel intermediate for producing pesticides. A method for producing the compound of formula (3) comprises reacting an aromatic ketone compound of formula (4) and a substituted acetophenone compound of formula (5) as starting raw materials in an organic solvent or water in the presence or absence of an additive in the presence of a base in a suspended state.
Nissan Chemical Industries, Ltd.
04/30/15
20150118698
 Biochemical markers for cvd risk assessment patent thumbnailBiochemical markers for cvd risk assessment
A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events..
Nordic Biociences A/s
04/30/15
20150118309

Preparation for percutaneous absorption containing rotigotine


Exemplary embodiments of the present invention relate to a method for preparing a preparation for percutaneous absorption, which includes rotigotine as an active ingredient, and more specifically, to a method for preparing a preparation for percutaneous absorption including mixing rotigotine and an ethylene-vinyl acetate adhesive so as to have a weight ratio of 1:(0.1 to 20), a preparation for percutaneous absorption manufactured by the method, and a percutaneous treatment system. The preparation and the system may prevent separation of the rotigotine, thereby increasing long-term storage stability, and effectively release the rotigotine, and thus can be effectively applied to preparing patch medication containing the rotigotine..
Sk Chemicals Co., Ltd.
04/30/15
20150118282

Transdermally absorbable preparation containing rotigotine


A method for preventing the precipitation of rotigotine crystals, including a step of mixing rotigotine and one or more crystallization prevention agents selected from the group consisting of fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, and the derivatives thereof, and to a transdermally absorbable preparation that includes rotigotine and crystallization prevention agents.. .
Sk Chemicals Co., Ltd.
04/23/15
20150112359

Electrical stimulation of the carotid artery


In order to treat hypertension, an implantable receiving device is connected to implantable leads which are adapted to deliver electrical energy to the carotid body or bodies of the patient. The receiving device is arranged to receive electoral energy from an external generator.
Bioinduction Limited
04/23/15
20150111947

Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage


Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases mitogen-activated protein kinase kinase kinase kinase 4 (map4k4) mrna expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases map4k4 mrna expression in an endothelial cell and additional therapeutic agents..
University Of Massachusetts
04/23/15
20150111872

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .
04/23/15
20150111824

Pharmaceutical formulations comprising incretin mimetic peptide and aprotic polar solvent


The present disclosure is directed to stable pharmaceutical formulations and uses thereof.. .
Astrazeneca Pharmaceuticals Lp
04/23/15
20150110895

Methods of treating necrotic enteritis


Methods of treating necrotic enteritis are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.. .
Liveleaf, Inc.
04/16/15
20150104462

Use of semaphorin-4d binding molecules for treatment of atherosclerosis


Provided herein are methods for reducing, inhibiting, suppressing and/or delaying atherosclerotic plaque growth or neovascularization in a subject having atherosclerosis, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4d (sema4d) or to its high affinity plexin-b1 receptor.. .
Vaccinex, Inc.
04/09/15
20150099919

Control of magnetic rotors to treat therapeutic targets


A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources.
Pulse Therapeutics, Inc.
04/02/15
20150094465

N-alkoxyamide conjugates as imaging agents


The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided.
Lantheus Medical Imaging, Inc.
04/02/15
20150094384

Methods for predicting and treating necrotizing enterocolitis in neonates


Embodiments are presented herein that provide early prediction of the development of necrotizing enterocolitis by a preterm infant through analysis of the high frequency component of heart rate variability, optionally with analysis of respiration rate. Methods of treatment following prediction area also reported..
The Penn State Research Foundation
03/26/15
20150086627

Dosage forms of halofuginone and methods of use


Oral and parenteral dosage forms comprising halofuginone, including enteric-coated solid oral dosage forms, subcutaneous dosage forms and intravenous dosage forms, for administration to subjects in need thereof, e.g., subjects having been identified with musculoskeletal disorders, fibrotic diseases, malaria, or cancer are described herein.. .
Halo Therapeutics, Llc.
03/26/15
20150086596

Organophosphates for treating afflictions of the skin


Embodiments of the invention involve treating skin afflictions by the topical or oral use of organophosphates. By effectively reducing or eliminating the population of demodex mites in affected skin areas and areas where demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method.
03/26/15
20150086529

Therapeutic burn gel


Therapeutic radiation burn gel is an invention that promotes the healing of radiated skin. It works by softening the layers of necrotic tissue which form (in the skin) post radiation.
03/26/15
20150086515

Imaging-aided gene therapy using mesenchymal stem cells as target-delivery vehicle


Compositions and methods of use thereof encompass engineered mesenchymal stem cells as a vehicle to deliver secreted tissue necrosis factor-rgd4c fusion polypeptides for tumor treatment, thereby reducing side effects of tnf. A reporter gene can be included in vector constructs to monitor the localization and viability of engineered mscs after administration into a recipient animal.
The Board Of Trustees Of The Leland Stanford Junior University
03/19/15
20150080686

Atherosclerotic plaque detection


An apparatus detects atherosclerotic plaques. The apparatus includes an electronic processing device that determines a level of fluorescence sensed by a sensor at a second infrared wavelength in response to exposure of at least part of an artery to radiation at a first infrared wavelength and determines a fluorescence indicator using the level of fluorescence.
Baker Idi Heart & Diabetes Institute Holdings Limited
03/19/15
20150080320

Multi-target modulation for treating fibrosis and inflammatory conditions


The present invention relates to compositions comprising one or more active agents that selectively modulate the expression of two or more genes, for example at the post-transcription level, that are involved in fibrosis and/or inflammatory conditions. Also provided are methods of using such compositions for treating fibrotic diseases, as well as other diseases including inflammatory diseases and cancer..
Aadigen, Llc
03/19/15
20150079055

Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease


An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the h-1, h-2, lewisb and lewisy antigens and derivatives thereof (e.g., a sialylated form of lewis a, lewis x, lewis b, lewis y; h-1, h-2, lewis a, lewis x, lewis b or lewis y)..
Instituto Nacional De Ciencias Medicas Y Nutricion
03/19/15
20150078997

N-alkoxyamide conjugates as imaging agents


The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided.
Lantheus Medical Imaging, Inc.
03/12/15
20150073400

Tissue treatment


There is provided in accordance with an exemplary embodiment of the invention a method and/or a device of treating tissue near a first lumen comprising inserting an energy emission element into a second lumen and delivering energy in an amount sufficient to cause one or more spaced apart areas of tissue damage at preselected locations in tissue near the first lumen. There is also provided a method and/or a device for treating a carotid artery wall, for example, to reduce signal conduction.
Cardiosonic Ltd.
03/12/15
20150072962

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis


5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virgini Commonwealth University
03/05/15
20150065947

Cell-seeded compositions and methods useful for treating bone regions


Compositions and methods for treating diseased or damaged bone, preferably ischemic and/or necrotic bone, include the use of a combination of endothelial progenitor cells and mesenchymal stem cells, desirably also in conjunction with a collagenous extracellular matrix tissue. Methods for preparation of such compositions are also described..
Muffin Incorporated
02/26/15
20150057216

Angiotensins for treatment of fibrosis


The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (copd), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided..
Tarix Pharmaceuticals Ltd.
02/26/15
20150056217

Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4 associated disorders


The present invention relates to the use of a tlr9 agonist and/or a tlr4 antagonist and/or a nod2 agonist for treatment or prevention of disorders involving tlr4 activation, such as systemic sepsis and necrotizing enterocolitis.. .
University Of Pittsburgh - Of The Commonwealth System Of Highter Education
02/26/15
20150056133

Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease


The present invention relates to cx3cr1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain cx3cr1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described.
02/19/15
20150051215

Pi3k inhibitors for treating fibrotic diseases


The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (ipf).. .
Glaxosmithkline Intellectual Property (no.2) Limited
02/19/15
20150048821

Atherosclerosis characterization using a multi-contrast mri sequence


The present invention relates to imaging and characterizing atherosclerotic lesions. The invention utilizes a low-flip-angle gradient echo-based mri acquisition technique combined with specialized magnetization preparative schemes (i.e.
Cedars-sinai Medical Center
02/12/15
20150045675

Percutaneous methods and devices for carotid body ablation


Methods and percutaneous devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via percutaneous carotid body ablation.. .
02/12/15
20150045403

Pharmaceutical cream compositions and methods of use


Embodiments relating to cream formulations as well as oxymetazoline creams and methods for treating rosacea and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith; other inflammatory conditions of the skin including, but not limited to, keratosis pilaris, lupus miliaris dissemniatus faciei, eczema, dermatitis, such as contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, statis dermatitis, neurodermatitis, lichen simplex chronicus, xerosis and xerotic dermatitis, dyshidrosis and dyshidrotic dermatitis, asteototic dermatitis or other conditions characterized by sensitive skin or a disturbance of the epidermal barrier; disorders characterized by rough, dry, cracked or fissured skin, disorders characterized by hyperkeratotic skin such as keratodermas and ichthyosisis and ichthyosiform dermatoses; disorders of hair follicles and sebaceous glands, such as acne, perioral dermatitis, and pseudofolliculitis barbae; disorders of sweat glands, such as miliaria, including, but not limited to, miliaria crystallina, miliaria rubra, miliaria profunda, miliaria pustulosa; sunburn, chronic actinic damage, poikiloderma, radiation dermatitis, actinic purpura (“solar purpura”); other inflammatory dermatoses, reactions and conditions of the skin, including, but not limited to, psoriasis, drug eruptions, erythema multiforme, erythema nodosum, and granuloma annulare; diseases and conditions characterized by bleeding or bruising such as petechiae, ecchymosis, purpura and the like including any accumulation of blood in the skin due to vascular extravasation, irrespective of size or cause, bleeding or bruising due to any skin injury which may include any trauma including surgical or procedural trauma; infection, inflammatory dermatoses or inflammation due to any cause using such creams are described herein.. .
Allergan, Inc.
02/05/15
20150038405

Pharmaceutical composition for preventing or treating arteriosclerosis


The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of seq id no: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis..
Eyegene, Inc.
02/05/15
20150037399

Novel use of pipoxolan and its pharmaceutical composition


The present disclosure concerns the novel use of pipoxolan and its pharmaceutical composition. Pipoxolan is useful therapeutic drugs for pathological conditions caused by vascular smooth muscle cell proliferation and migration to relieve a body appeared vascular injury, cerebrovascular ischemia, intimal hyperplasia, atherosclerotic stenosis, cerebral ischemia, and stroke..
China Medical University
01/29/15
20150032197

Carotid stent assembly and methods for treatment via body lumens


A stent assembly adapted to carotid arterial placement that includes a self-expanding support element comprising metal struts constructed to be positioned in a body lumen and expanded from a retracted state to an expanded state, and a knitted cover disposed over an exterior of the support element and along an entire length thereof, wherein the knitted cover comprises a single polymer fiber having a diameter of at least 40 nanometers to 30 microns, wherein the self-expanding support element and knitted cover together have apertures sized 20 microns to smaller than 100 microns in diameter to block larger debris when the stent assembly is placed in a carotid artery and expanded to the expanded state. Methods of stenting a carotid artery by applying the stent assembly to the carotid artery of a patient in need of treatment and expanding the stent assembly in situ are disclosed..
Inspiremd, Ltd
01/22/15
20150025616

Method and treating a carotid artery


One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery..
Silk Road Medical, Inc.
01/15/15
20150018942

Method of implanting an aortic stent


A method of implanting an aortic stent comprising steps of: putting a main tube on a metal guide wire; moving the main tube along the metal guide wire to the descending aorta, the main tube is constrained by a first cover, and first and second tube bifurcations are branched from the main section; removing the first cover; inserting a second and third metal guide wire through the first tube bifurcation into the ascending aorta and branchiocephalic artery respectively; a first and a second tube branch moving into the ascending aorta and the branchiocephalic artery respectively; inserting a fourth and fifth metal guide wire through the first tube bifurcation into the ascending aorta and branchiocephalic artery respectively; a third and a fourth tube branch moving into left common carotid artery and the left subclavian artery respectively; removing a second cover constraining said tube branches.. .


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.8225

3649

3 - 0 - 71